Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution
Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.
Why Immunome’s RINGSIDE data may reset expectations in desmoid tumor treatment
Discover how Immunome’s Phase 3 RINGSIDE data could reshape desmoid tumor treatment and gamma secretase inhibitor competition.
Immunome’s Phase 3 varegacestat data could redefine gamma secretase inhibition in desmoid tumors
Immunome is set to release pivotal Phase 3 varegacestat data in desmoid tumors. Find out what the RINGSIDE results could change for the field.